Alexion Pharmaceuticals AAQS 2024
Alexion Pharmaceuticals AAQS
Alexion Pharmaceuticals Randamentul dividendelor
Ticker
ISIN
WKN
Alexion Pharmaceuticals are un AAQS curent de 0. Un AAQS ridicat poate fi considerat ca un indiciu pozitiv că întreprinderea se dezvoltă cu succes. Investitorii pot presupune că întreprinderea este pe drumul cel bun pentru a realiza profituri. Pe de altă parte, este important să se evalueze AAQS-ul acțiunii Alexion Pharmaceuticals în comparație cu profiturile generate și cu alte companii din aceeași industrie. Un AAQS ridicat nu este o garanție absolută pentru un viitor pozitiv. Numai așa se poate obține o imagine completă a performanței întreprinderii. Pentru a putea evalua mai bine evoluția întreprinderii, este esențial să se compare AAQS-ul cu cel al altor companii din aceeași industrie. În general, investitorii ar trebui să analizeze AAQS-ul unei întreprinderi în contextul altor indicatori financiari precum profitul, EBIT, fluxul de numerar și alții, pentru a lua o decizie de investiții bine fundamentată.
Alexion Pharmaceuticals Aktienanalyse
Ce face Alexion Pharmaceuticals?
Alexion Pharmaceuticals Inc. is a US biotechnology company specializing in the development and commercialization of drugs for the treatment of rare diseases. It was founded in 1992 and is headquartered in Boston, Massachusetts. The history of Alexion began with the discovery of the protein C5a, which is responsible for the occurrence of inflammation. Alexion then developed the first medication, Soliris, specifically for the treatment of the rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH). Soliris is classified as a monoclonal antibody and inhibits the protein C5a, which is responsible for inflammation. Alexion's business model focuses primarily on developing drugs for rare diseases. These diseases are unprofitable for most major pharmaceutical companies because they have a small patient base. However, Alexion has begun to identify and develop drugs for such diseases that are tailored to these specific patients. Such drugs are not suitable for the majority of the patient population as they are very expensive. Alexion is divided into several divisions focused on the development and launch of drugs for specific diseases. The most well-known division is PNH, but the company has also developed drugs for rare hematological, nephrological, neurological, immunological, and metabolic diseases. Alexion has also developed the ability to bring drugs to market faster than other pharmaceutical companies by employing innovative clinical trial methods. In addition to Soliris, Alexion has developed other drugs such as Ultomiris, Strensiq, and Kanuma. Ultomiris is a successor to Soliris and is used to treat PNH and aHUS. Strensiq is used for patients with hypophosphatasia, while Kanuma was developed for patients with lysosomal storage diseases such as children with Gaucher disease or Fabry disease. Alexion also collaborates with other companies to develop and market drugs for rare diseases. The most well-known example is the collaboration with the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation to develop the drug ALXN1210, which Alexion hopes will surpass both Soliris and Ultomiris. The collaboration has the potential to provide groundbreaking treatment for PNH, aHUS, and other rare diseases. Overall, in recent years, Alexion Pharmaceuticals Inc. has become an important player in the market for rare diseases. The company has taken on challenging tasks by striving to uncover rare diseases and gaps and then finding new, unique solutions to treat these diseases. In the future, Alexion will continue its efforts in researching and developing drugs for rare diseases and will continue to provide innovative solutions and therapeutic approaches to improve the lives of patients. Alexion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.Alexion Pharmaceuticals Cifra de afaceri pe segment
În raportul anual al acțiunii Alexion Pharmaceuticals (US0153511094, 899527, ALXN), își împarte veniturile în 1 segmente: 1. Therapies. Acțiunea Alexion Pharmaceuticals (WKN: 899527, ISIN: US0153511094, simbol Ticker: ALXN) este un investiție de frunte pentru investitorii interesați de participarea în sectorul Health Care.
Întrebări frecvente despre acțiunea Alexion Pharmaceuticals
Acțiunea Alexion Pharmaceuticals este disponibilă pentru planuri de economii la următorii furnizori: Trade Republic
Andere Kennzahlen von Alexion Pharmaceuticals
Analiza noastră a acțiunilor pentru acțiunea Alexion Pharmaceuticals Vânzări include indicatori financiari importanți precum cifra de afaceri, profitul, raportul preț/profit (P/E), raportul preț/venit (P/S), EBIT, precum și informații referitoare la dividend. De asemenea, examinăm aspecte precum acțiunile, capitalizarea de piață, datoriile, capitalul propriu și obligațiile companiei Alexion Pharmaceuticals Vânzări. Dacă căutați informații mai detaliate legate de aceste subiecte, vă oferim pe paginile noastre secundare analize amănunțite.
- Alexion Pharmaceuticals Vânzări
- Alexion Pharmaceuticals Profit
- Alexion Pharmaceuticals P/E
- Alexion Pharmaceuticals Cifra de afaceri pe acțiune (KUV)
- Alexion Pharmaceuticals EBIT
- Alexion Pharmaceuticals Dividend
- Alexion Pharmaceuticals Acțiuni
- Alexion Pharmaceuticals Capitalizare de piață
- Alexion Pharmaceuticals Datorie
- Alexion Pharmaceuticals Datorii
- Alexion Pharmaceuticals Capital propriu
- Alexion Pharmaceuticals AAQS
- Alexion Pharmaceuticals Angajați
- Alexion Pharmaceuticals ROE
- Alexion Pharmaceuticals ROA
- Alexion Pharmaceuticals ROCE